In diffuse large B-cell lymphoma (DLBCL), concomitant overexpression of BCL-2 and MYC is classified as a “double-hit” DLBCL, which is associated with a dismal prognosis, high risk for relapse, resistance to standard chemotherapy and justifies upfront escalation to more intensive treatment. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.